Probi Digestis®

Overview

Probi Digestis® is based on the probiotic strain Lactiplantibacillus plantarum 299v (LP299V®). LP299V® has been documented within several areas, all related to health benefits in the gut. It is described in more than 200 scientific publications and has been subject to more than 70 clinical studies. Clinical results have been shown within areas reaching from inflammation to metabolic health, with the major benefit being relief of symtpoms coupled to IBS. The clinically documented dose is 10 billion (10 B) CFU per day.

Probi Digestis® and LP299V® are registered trademarks of Probi AB.

Watch the probiotic mode of action of Probi Digestis®:

Scientific reference(s)

Over 70 human clinical studies.

Ducrotte, P., P. Sawant, and V. Jayanthi, Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol, 2012. 18(30): p. 4012-8.

Niedzielin, K., H. Kordecki, and B. Birkenfeld, A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol, 2001. 13(10): p.
1143-7.

Nobaek, S., et al., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol, 2000. 95(5): p. 1231-8.

Krammer, H., et al., [Treatment of IBS with Lactobacillus plantarum 299v: Therapeutic success increases with length of treatment - real-life data of a non-interventional study in Germany]. Z Gastroenterol, 2021 . 59(2): p. 125-134.

Kujawa-Szewieczek A, Adamczak M, Kwiecień K, Dudzicz S, Gazda M, Więcek A. (2015) The Effect of Lactobacillus plantarum299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics. Nutrients. 4;7(12):10179-88.

Mack, D.R., et al., Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol, 1999. 276(4): p. G941-50.

Mack, D.R., et al., Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut, 2003. 52(6): p. 827-33.

Adlerberth, I., et al., A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29. Appl Environ Microbiol, 1996. 62(7): p. 2244-51.

Additional info

Therapeutical area(s)

Cardiometabolic · Gastrointestinal tract · Gut brain Axis · Healthy ageing

Functionality

Constipation · Gut permeability · IBS

Age/Gender

Adults · Children · Elderly

Dosage form

CFU/Dose

Probi Digestis® is available at

Probi AB

Probiotics, LBPs, prebiotics & postbiotics + Production & Manufacturing